US 11,052,111 B2
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
Benjamin Wang, Menlo Park, CA (US); and Gusti Zeiner, Pacifica, CA (US)
Assigned to Chimera Bioengineering, Inc., Menlo Park, CA (US)
Filed by Chimera Bioengineering, Inc., Menlo Park, CA (US)
Filed on Dec. 5, 2016, as Appl. No. 15/369,132.
Claims priority of provisional application 62/264,771, filed on Dec. 8, 2015.
Claims priority of provisional application 62/276,449, filed on Jan. 8, 2016.
Prior Publication US 2017/0157176 A1, Jun. 8, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); C12N 5/10 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 35/28 (2015.01); A61K 35/12 (2015.01)
CPC A61K 35/17 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C12N 5/10 (2013.01); A61K 35/28 (2013.01); A61K 2035/124 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2310/12 (2013.01)] 5 Claims
 
1. A method of killing a target cell comprising the steps of: obtaining a T-cell comprising a RNA control device comprised of a sensor element and a ribozyme element, and a polynucleotide encoding a CAR, wherein the CAR is comprised of an extracellular element, a transmembrane element, and an intracellular element, wherein the transmembrane element is between the extracellular element and the intracellular element, wherein the RNA control device is operably linked to the polynucleotide encoding the CAR, exposing the T-cell to a ligand for the sensor element whereby the CAR is expressed on the surface of the T-cell; and exposing the T-cell to the target cell whereby killing of the target cells is increased compared to a T-cell that constitutively expresses the CAR.